Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04870255 · ClinicalTrials.gov registry record · NA
Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS
A NA study of Depressive Disorder, Major and Borderline Personality Disorder, sponsored by Stanford University.
- Active
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT04870255: Active NA study of Depressive Disorder, Major and Borderline Personality Disorder, sponsored by Stanford University.
NCT04870255 is a NA study of Depressive Disorder, Major and Borderline Personality Disorder that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 45 participants, below the 241-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04870255, a NA study of Depressive Disorder, Major and Borderline Personality Disorder, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the antidepressant effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), in individuals with borderline personality disorder (BPD) or trait and comorbid mood depressive disorder (MDD) or bipolar II disorder in a current mood depressive episode (MDE).
Primary Outcome
A ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders.The MADRS-C has an overall score range from 0-60, with higher scores corresponding to higher levels of depression.
Conditions Studied
Interventions
- DEVICE Sham Stimulation
- DEVICE Left Dorsolateral Prefrontal Cortex (L-DLPFC)
- DEVICE Dorsomedial Prefrontal Cortex (DMPFC)
Study Locations (1)
California
- Stanford Hospital - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-07-20 |
| Est. Completion | 2026-12 |
| Phase | NA |
What the registry record for NCT04870255 still lists
NCT04870255 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 241-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Depressive Disorder, Major appearing as the primary indexed condition, and to 3 interventions - of which Sham Stimulation is the first listed.
NCT04870255 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04870255 about?
NCT04870255 is a clinical study titled "Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS". This study evaluates the antidepressant effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), in individuals with borderline personality disorder (BPD) or trait and comorbid mood depressive disorder (MDD) or bipolar II disorde...
What is the current status of trial NCT04870255?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2021-07-20. Estimated completion is 2026-12.
What conditions does trial NCT04870255 study?
This clinical trial studies the following conditions: Depressive Disorder, Major, Borderline Personality Disorder.
What interventions are being tested in trial NCT04870255?
The interventions under investigation include: Sham Stimulation (DEVICE), Left Dorsolateral Prefrontal Cortex (L-DLPFC) (DEVICE), Dorsomedial Prefrontal Cortex (DMPFC) (DEVICE).
Who is sponsoring clinical trial NCT04870255?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04870255 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04870255's enrollment target sits among peer trials
45 40th of 52 higher than 13 of 52 other Depressive Disorder, Major trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Major trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI
RECRUITING · NA
-
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
RECRUITING · NA
-
Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness
RECRUITING · NA
-
Biomarkers of Depression and Treatment Response
RECRUITING · NA
-
In-person vs. Remote Wellness Support
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI